These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23113687)

  • 1. HLA-DM: arbiter conformationis.
    Ferrante A
    Immunology; 2013 Feb; 138(2):85-92. PubMed ID: 23113687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DM catalytically enhances peptide dissociation by sensing peptide-MHC class II interactions throughout the peptide-binding cleft.
    Reyes-Vargas E; Barker AP; Zhou Z; He X; Jensen PE
    J Biol Chem; 2020 Mar; 295(10):2959-2973. PubMed ID: 31969393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct editing functions of natural HLA-DM allotypes impact antigen presentation and CD4
    Álvaro-Benito M; Morrison E; Ebner F; Abualrous ET; Urbicht M; Wieczorek M; Freund C
    Cell Mol Immunol; 2020 Feb; 17(2):133-142. PubMed ID: 30467419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DM and DO shape the repertoire of peptide-MHC-class-II complexes.
    Karlsson L
    Curr Opin Immunol; 2005 Feb; 17(1):65-70. PubMed ID: 15653313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide.
    Yin L; Trenh P; Guce A; Wieczorek M; Lange S; Sticht J; Jiang W; Bylsma M; Mellins ED; Freund C; Stern LJ
    J Biol Chem; 2014 Aug; 289(34):23449-64. PubMed ID: 25002586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism.
    Guce AI; Mortimer SE; Yoon T; Painter CA; Jiang W; Mellins ED; Stern LJ
    Nat Struct Mol Biol; 2013 Jan; 20(1):90-8. PubMed ID: 23222639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of peptide repertoire selection by HLA-DM.
    Pos W; Sethi DK; Wucherpfennig KW
    Trends Immunol; 2013 Oct; 34(10):495-501. PubMed ID: 23835076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational variation in structures of classical and non-classical MHCII proteins and functional implications.
    Painter CA; Stern LJ
    Immunol Rev; 2012 Nov; 250(1):144-57. PubMed ID: 23046127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules.
    Vogt AB; Kropshofer H; Hämmerling GJ
    Hum Immunol; 1997 May; 54(2):170-9. PubMed ID: 9297535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway.
    Schulze MS; Wucherpfennig KW
    Curr Opin Immunol; 2012 Feb; 24(1):105-11. PubMed ID: 22138314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity.
    Jiang W; Strohman MJ; Somasundaram S; Ayyangar S; Hou T; Wang N; Mellins ED
    Sci Rep; 2015 Nov; 5():17333. PubMed ID: 26610428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting nonclassical HLA II functions in antigen presentation: Peptide editing and its modulation.
    Álvaro-Benito M; Freund C
    HLA; 2020 Oct; 96(4):415-429. PubMed ID: 32767512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination.
    Yin L; Stern LJ
    J Immunol Methods; 2014 Apr; 406():21-33. PubMed ID: 24583195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short peptide sequences mimic HLA-DM functions.
    Chou CL; Mirshahidi S; Su KW; Kim A; Narayan K; Khoruzhenko S; Xu M; Sadegh-Nasseri S
    Mol Immunol; 2008 Apr; 45(7):1935-43. PubMed ID: 18054387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-DM mediates epitope selection by a "compare-exchange" mechanism when a potential peptide pool is available.
    Ferrante A; Anderson MW; Klug CS; Gorski J
    PLoS One; 2008; 3(11):e3722. PubMed ID: 19005572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation.
    Poluektov YO; Kim A; Hartman IZ; Sadegh-Nasseri S
    PLoS One; 2013; 8(8):e71228. PubMed ID: 23951115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules.
    Kropshofer H; Hämmerling GJ; Vogt AB
    Immunol Rev; 1999 Dec; 172():267-78. PubMed ID: 10631952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives.
    Yin L; Calvo-Calle JM; Dominguez-Amorocho O; Stern LJ
    J Immunol; 2012 Oct; 189(8):3983-94. PubMed ID: 22966084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-DM Focuses on Conformational Flexibility Around P1 Pocket to Catalyze Peptide Exchange.
    Yin L; Stern LJ
    Front Immunol; 2013 Oct; 4():336. PubMed ID: 24146666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.